Jianhua Rao1, Ling Lu, Yuan Zhai. 1. aDumont-UCLA Transplant Center, Division of Liver and Pancreas Transplantation, Department of Surgery, David Geffen School of Medicine at University of California-Los Angeles, Los Angeles, California, USA bLiver Transplantation Center, Department of Liver Surgery, First Affiliated Hospital of Nanjing Medical University Nanjing, Jiangsu Province, China.
Abstract
PURPOSE OF REVIEW: Ischemia and reperfusion injuries occur in multiple clinical settings and contribute to organ dysfunction/failures. Despite the innate inflammatory immune nature, T cells that are critically involved in the pathogenesis of ischemia reperfusion injury (IRI), include not only CD4+ T cells, but also CD8+ and γδT cells. This review focuses on questions of how putative Ag-specific T cells are involved, which include whether they function in an Ag-dependent manner; how they function, cytokine-mediated or costimulatory molecule-mediated mechanisms; and whether different T-cell subsets, Th1, Th17, regulatory T cell (Treg), are all involved and play distinctive roles? RECENT FINDINGS: Specific T-cell populations, such as effector memory CD4 T cells, promote inflammatory immune activation by ischemia reperfusion independent of their adaptive properties, that is Ag-independently. They function by secreting cytokines and expressing costimulatory molecules to either promote or inhibit innate immune activation, or facilitate tissue repair/homeostasis, as exemplified by Th1, Th17 or Th2, Treg cells, respectively. SUMMARY: T-cell-targeted therapies need to be refined with strategies to maximally eliminate the proinflammatory but spare the anti-inflammatory/immune regulatory properties of T cells, for future clinical application to ameliorate IRI.
PURPOSE OF REVIEW: Ischemia and reperfusion injuries occur in multiple clinical settings and contribute to organ dysfunction/failures. Despite the innate inflammatory immune nature, T cells that are critically involved in the pathogenesis of ischemia reperfusion injury (IRI), include not only CD4+ T cells, but also CD8+ and γδT cells. This review focuses on questions of how putative Ag-specific T cells are involved, which include whether they function in an Ag-dependent manner; how they function, cytokine-mediated or costimulatory molecule-mediated mechanisms; and whether different T-cell subsets, Th1, Th17, regulatory T cell (Treg), are all involved and play distinctive roles? RECENT FINDINGS: Specific T-cell populations, such as effector memory CD4 T cells, promote inflammatory immune activation by ischemia reperfusion independent of their adaptive properties, that is Ag-independently. They function by secreting cytokines and expressing costimulatory molecules to either promote or inhibit innate immune activation, or facilitate tissue repair/homeostasis, as exemplified by Th1, Th17 or Th2, Treg cells, respectively. SUMMARY: T-cell-targeted therapies need to be refined with strategies to maximally eliminate the proinflammatory but spare the anti-inflammatory/immune regulatory properties of T cells, for future clinical application to ameliorate IRI.
Authors: Elke Eggenhofer; Jordi Rovira; Manije Sabet-Baktach; Anja Groell; Marcus N Scherer; Marc-Hendrik Dahlke; Stefan A Farkas; Martin Loss; Gudrun E Koehl; Sven A Lang; Michael Melter; Hans J Schlitt; Edward K Geissler; Alexander Kroemer Journal: J Immunol Date: 2013-06-05 Impact factor: 5.422
Authors: M J Burne; F Daniels; A El Ghandour; S Mauiyyedi; R B Colvin; M P O'Donnell; H Rabb Journal: J Clin Invest Date: 2001-11 Impact factor: 14.808
Authors: Mathias Gelderblom; Anna Weymar; Christian Bernreuther; Joachim Velden; Priyadharshini Arunachalam; Karin Steinbach; Ellen Orthey; Thiruma V Arumugam; Frank Leypoldt; Olga Simova; Vivien Thom; Manuel A Friese; Immo Prinz; Christoph Hölscher; Markus Glatzel; Thomas Korn; Christian Gerloff; Eva Tolosa; Tim Magnus Journal: Blood Date: 2012-09-13 Impact factor: 22.113
Authors: Christoph Kleinschnitz; Peter Kraft; Angela Dreykluft; Ina Hagedorn; Kerstin Göbel; Michael K Schuhmann; Friederike Langhauser; Xavier Helluy; Tobias Schwarz; Stefan Bittner; Christian T Mayer; Marc Brede; Csanad Varallyay; Mirko Pham; Martin Bendszus; Peter Jakob; Tim Magnus; Sven G Meuth; Yoichiro Iwakura; Alma Zernecke; Tim Sparwasser; Bernhard Nieswandt; Guido Stoll; Heinz Wiendl Journal: Blood Date: 2012-11-15 Impact factor: 22.113
Authors: Y Zhang; H Ji; X Shen; J Cai; F Gao; K M Koenig; C M Batikian; R W Busuttil; J W Kupiec-Weglinski Journal: Am J Transplant Date: 2012-11-08 Impact factor: 8.086
Authors: T Tanabe; H Watanabe; J A Shah; H Sahara; A Shimizu; S Nomura; A Asfour; M Danton; L Boyd; A Dardenne Meyers; D K Ekanayake-Alper; D H Sachs; K Yamada Journal: Am J Transplant Date: 2017-03-03 Impact factor: 8.086
Authors: Maximilian Kueckelhaus; Sebastian Fischer; Midas Seyda; Ericka M Bueno; Mario A Aycart; Muayyad Alhefzi; Abdallah ElKhal; Bohdan Pomahac; Stefan G Tullius Journal: Transpl Int Date: 2015-09-14 Impact factor: 3.782
Authors: Philip J Vernon; Leasha J Schaub; Jurandir J Dallelucca; Anthony E Pusateri; Forest R Sheppard Journal: PLoS One Date: 2015-12-30 Impact factor: 3.240
Authors: Anthony D Foster; Diego Vicente; Jonathan J Sexton; Luke Johnston; Nick Clark; Crystal Leonhardt; Eric A Elster; Thomas A Davis; Matthew J Bradley Journal: Mediators Inflamm Date: 2017-12-19 Impact factor: 4.711